New drug combo aims to slow lung damage in rare muscle disease
NCT ID NCT05799755
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding nintedanib (OFEV) to standard immunosuppressant therapy can improve symptoms in people with myositis-associated interstitial lung disease, a condition where lung tissue becomes scarred and stiff. 49 adults in the U.S. participated, receiving either nintedanib or a placebo alongside their usual medications. The main goal was to measure changes in breathing-related quality of life using a questionnaire.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nintedanib (also known as OFEV)
What this could lead to
If it works, this could provide a new treatment option to slow lung scarring and improve breathing in people with myositis-related lung disease.
What could go wrong
This is an early exploratory trial with only 49 participants, so results may not be conclusive. Nintedanib can cause side effects like diarrhea and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOSITIS ASSOCIATED INTERSTITIAL LUND DISEASE (MA-ILD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Mayo Clinic Arizona
Scottsdale, Arizona, 85259, United States
-
National Jewish Health
Denver, Colorado, 80206, United States
-
Northwell Health
New York, New York, 11021, United States
-
University of Alabama
Birmingham, Alabama, 35294, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15216, United States
-
University of South Florida
Tampa, Florida, 33612, United States
-
University of Utah Health Sciences Center
Salt Lake City, Utah, 84112, United States